Chronic Pain Market Poised for Growth at a CAGR of 5% During the Forecast Period (2026-2036), as Rising Patient Burden and Novel Treatment Approaches are Creating New Opportunities | DelveInsight

DelveInsight forecasts the chronic pain market across the US, EU4, UK and Japan to grow at a 5% CAGR from a $15 billion base in 2025, supported by approximately 115 million diagnosed prevalent cases. Growth is expected to be driven by demand for non-opioid treatments and a broad late-stage pipeline, including Saol's SL-1002, Paradigm's injectable PPS, Amzell's AMZ001 and Grünenthal/NovaQuest's resiniferatoxin. Near-term catalysts include Paradigm's PPS interim analysis expected in September 2026 and Phase III topline results anticipated in Q1 2027, alongside multiple positive or advancing Phase III programs.

Analysis

The investable implication is not broad chronic-pain market growth; it is differentiation between therapies that can earn formulary access and those that merely add another symptomatic option. Payers will demand opioid avoidance, durable functional improvement, and reduced procedure/retreatment costs before granting premium reimbursement. This favors Vertex (VRTX) if NaV1.8-based analgesia can translate beyond acute pain without safety trade-offs, while topical NSAIDs, legacy opioids and undifferentiated injectables face generic pricing and step-edit pressure.

GLP-1/next-generation incretin data introduce a less obvious substitution risk to knee-OA pain franchises: sustained weight reduction can lower pain and delay injections or joint replacement, shrinking the addressable treated population even as the diagnosed population grows. Lilly (LLY) has the nearer-term narrative advantage from retatrutide-associated OA-pain data, but neither LLY nor Novo Nordisk (NVO) should receive meaningful valuation credit for pain alone until dedicated studies establish clinically relevant benefit, persistence and reimbursement. NVO's dedicated OA timeline pushes any direct pain catalyst well beyond the next 12 months.

This release is promotional market research rather than independent evidence and should not itself move large-cap pharma. The more actionable near-term binary is small-cap development: Mesoblast (MESO), Scilex (SCLX), Lexicon (LXRX) and Axsome (AXSM) can re-rate on trial execution, but each requires a clear endpoint, safety and commercial-access case; enrollment milestones alone do not de-risk approval. The contrarian view is that an expanding pipeline may compress, rather than expand, realized pricing as several modalities compete for the same refractory OA and back-pain patients.

Key Decisions for Investors

• Maintain/establish a 6-12 month long VRTX versus equal-dollar short XBI basket: VRTX has a differentiated non-opioid mechanism and chronic-pain label-expansion optionality, while diversified early-stage pain developers remain exposed to funding and endpoint risk. Reassess if chronic-pain development timelines slip, safety signals emerge, or commercial uptake of JOURNAVX misses the first two post-launch prescription inflections.
• Do not add LLY or NVO solely for pain exposure. Treat OA-pain improvement as upside optionality within obesity franchises; revisit after dedicated, peer-reviewed functional-outcome data and payer commentary. Falsifier for the substitution thesis: no sustained pain/function separation after weight loss or broad reimbursement exclusion for OA-related use.
• Put AXSM, MESO, SCLX and LXRX on event-driven watch rather than initiate on this release. Require disclosure of randomized efficacy versus standard care, durability through at least 6-12 months, discontinuation rates and a credible launch funding plan; absent these, expected dilution and commercialization spending can outweigh clinical-news upside.
• For investors seeking OA exposure, monitor privately held/foreign-listed Paradigm's September interim analysis and Q1 2027 pivotal readout as a sector sentiment catalyst, not a direct listed-equity trade. A statistically positive pain endpoint without structural/function benefit or a clean bleeding profile would still be insufficient to validate premium pricing.